PubMed HealthSearch

Biomedical subjects

H Reichard

Publications and source records attributed to H Reichard.

At least 19 recordsLinked to original sources

Flow cytometric DNA analysis in longstanding ulcerative colitis: a method of prediction of dysplasia and carcinoma development?

During a prospective study lasting 3.5 years flow cytometric DNA analysis was evaluated as a possible predictor of dysplastic and malignant lesions in longstanding ulcerative colitis. Fifty three patients with total ulcerative colitis (mean disease duration of 22 years) were regularly colonoscoped. Biopsies of colonic mucosa were analysed by flow cytometric technique and were also assessed histologically. Findings of abnormal DNA pattern (aneuploidy) were compared with findings of dysplasia. Five patients (9%) had aneuploidy, four of those at repeated colonoscopies. Four of those patients also had various degrees of dysplasia. In one patient aneuploidy preceded the finding of dysplasia and in another aneuploidy preceded a well differentiated adenocarcinoma, grade Dukes' A subsequently found at surgery. Four additional patients had dysplasia, all in connection with macroscopic lesions, but were diploid. It is suggested that flow cytometric DNA analysis in long standing ulcerative colitis may be helpful in addition to histopathology in the detection of potential malignancy in ulcerative colitis.

Adult

Cancer surveillance of patients with longstanding ulcerative colitis: a clinical, endoscopical, and histological study.

An eight year endoscopical and histological cancer surveillance programme comprising 71 patients with ulcerative colitis is presented. Forty one patients had total colitis and 30 substantial colitis. Mean duration of the disease was 19.7 years (range 9-46 years). An average of 2.6 colonoscopies per patient in the total colitis group were carried out, and at least two biopsies were taken at 10 locations in the colon. In the total colitis group, seven had either low (four), or high grade dysplasia (two), or Dukes' A cancer (one). In the group with substantial colitis two patients with low grade dysplasia were found. Dysplasia or cancer leading to operation was found above the rectum in four of five operated patients, all having had total colitis for 25 to 44 years. The dysplasia and cancer findings at the colonoscopy preceding surgery corresponded well with the surgical specimens. In three operated patients a sequence of dysplasia development was recorded. With the exception of long duration and dysplasia, nothing in the clinical course distinguished the operated cases. Using this surveillance programme prophylactic colectomy can be limited to patients in a high risk group developing dysplasia. The risk of missing a cancer before it becomes incurable seems to be low.

Adult

Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study.

In a double-blind trial of tranexamic acid in massive upper gastrointestinal haemorrhage, 76 patients were treated with the active drug and 73 patients with placebo. The doses were 1 g intravenously six times daily for a maximum of 3 days, followed by 1.5 g orally four times daily for a maximum of 4 days. The treatment group and the placebo group were comparable with respect to mean age, diagnoses and laboratory tests but differed slightly with respect to sex and alcohol consumption. The transfusion requirement in the treatment group was less than in the placebo group during the first days after admission, the difference being significant on the second day after admission. Ten patients in the treatment group and 18 patients in the placebo group were operated on. Eleven patients in the treatment group and 12 patients in the placebo group died. In the tranexamic-acid-treated group fewer operations were performed and significantly less blood was needed. It therefore seems highly likely that tranexamic acid has a beneficial effect, although small.

Aged

Double-blind trial of deglycyrrhizinated liquorice in gastric ulcer.

In order to investigate further the reported beneficial effect of deglycyrrhizinated liquorice in gastric ulcer, a trial with a double-blind, cross-over design was performed. The patients were treated during two consecutive periods of four weeks each with either liquorice extract during the first period and placebo during the second or placebo during the first period and liquorice during the second. Only patients with chronic ulcer disease were accepted for the trial. The dosage of the liquorice extract was 760 mg three times daily. During the first period 38 patients with 47 ulcers in the ventricle and during the second period 30 patients with 36 ulcers took part in the trial. The patients' sex, age, site of the ulcer in the ventricle, and ulcer size in the groups treated with liquorice and placebo during periods I and II were similar. Nor could any difference be shown between the groups treated with liquorice and placebo with respect to heredity, duration of ulcer disease, alcohol consumption, smoking, or the use of drugs. There was no tendency to quicker healing in either group as regards change of ulcer area or complete healing. Small ulcers healed more quickly than big ones. Ulcers at the angulus healed very poorly. No side effects of treatment were observed.Our study was not able to demonstrate any healing effect of the liquorice extract (Caved-S) on gastric ulcer.

Adult